How it Works
Talquetamab-tgvs, a bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager, is an antineoplastic agent.
How it’s Administered
Injection
3 mg/1.5 mL (2 mg/mL) in a single-dose vial for subcutaneous injection
40 mg/mL in a single-dose vial for subcutaneous injection
Who Should Take Talquetamab
Talquetamab-tgvs is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Who Shouldn’t Take Talquetamab
- Pregnant women (causes fetal harm when administered to a pregnant woman)
- Females and males of reproductive potential (verify pregnancy status prior to initiating talquetamab and advise females of reproductive potential to use effective contraception during treatment with talquetamab and for 3 months after the last dose)
- Females who are breastfeeding (there is no information regarding the presence of talquetamab in human milk, the effect on the breastfed child, or the effect on milk production)
- Children (the safety and efficacy of talquetamab have not been established in pediatric patients)
- Patients of 75 years of age of older (clinical studies did not include sufficient numbers of patients 75 years of age or over to determine whether they respond differently from younger patients)
The Most Common Side Effects of Taking Talquetamab Include:
- Cytokine Release Syndrome
- Neurologic Toxicity Including immune effector cell-associated neurotoxicity syndrome (ICANS)
- Headache
- Encephalopathy
- Sensory neuropathy
- Motor dysfunction
- Musculoskeletal pain
- Fatigue
- Decreased weight
- Pyrexia
- Dysgeusia
- Dry mouth
- Dysphagia
- Stomatitis
- Diarrhea
- Hypotension
- Infections
- Neutropenia
- Thrombocytopenia
- Leukopenia
- Anemia
- Rash
- Maculo-papular rash
- Erythema
- Erythematous rash
- Hepatotoxicity
- Embryo-fetal toxicity (causes fetal harm when administered to a pregnant woman)
Currently Being Tested With
- Daratumumab
- Daratumumab and Pomalidomide
- Daratumumab, Pomalidomide, and dexamethasone
- Teclistamab
- PD-1 inhibitor
Learn more about treatments in Cure Hub
For more information, go to https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf
Date last updated: 9/19/23
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
![Johnson and Johnson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJohnson%20&%20Johnson%20Logo_64b18f59-85c9-4c20-a5ff-3842e69d8066.jpg?alt=media)
![Sanofi](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FSanofi%20updated%202023_d25a8d12-4f09-410c-9eb1-1e725b0b7c3e.jpg?alt=media)
![Pfizer](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPfizer%20Logo%202024_50ae4587-5fdc-48e2-9a52-21651c643494.png?alt=media)
![Genentech](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/admin%2Fpublic%2Fshared%2FGenentech_Logo-700x182_e3c64168-dcf4-4540-9e9d-26500b26920a.png?alt=media)
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_dec43aa4-fe53-4d5a-9b7f-4170101b47f9.webp?alt=media)
![Adaptive](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FAdaptive%20Logo%204.2023_e0d11d37-8b31-4c88-a0fc-4d07efc9b16b.png?alt=media)